BioSight
Companies
Xeris Biopharma Holdings, Inc. logo

XERS

NASDAQCHICAGO, IL
Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings develops and commercializes injectable pharmaceuticals across endocrinology and acute care, with marketed products including Recorlev (for Cushing's syndrome), Gvoke (for hypoglycemia), and Keveyis (for periodic paralysis). The company also operates a formulation science platform focused on collaborating with other pharmaceutical companies to develop new drug formulations. Xeris is primarily in the commercialization stage for its existing products while maintaining a pipeline of product candidates in development.

Price history not yet available for XERS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar